GCSAM: A Potential Drug Target and Biomarker for Diseases (G257144)

Target Name: GCSAM

NCBI ID: G257144

GCSAM

GCSAM: A Potential Drug Target and Biomarker for Diseases

GCSAM, or germinal center expressed transcript 2, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. GCSAM is expressed in a variety of tissues and cells throughout the body and has been shown to play a role in the development and progression of these diseases.

GCSAM is a gene that encodes a protein known as GCSAM, which is expressed in a variety of tissues throughout the body. The protein is composed of 194 amino acids and has been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising aspects of GCSAM is its potential as a drug target. GCSAM has been shown to interact with several protein molecules, including the transcription factor NF-kappa-B and the protein PD-L1. These interactions suggest that GCSAM may be a useful target for drugs that are designed to inhibit the activity of these molecules.

In addition to its potential as a drug target, GCSAM has also been shown to be a valuable biomarker for several diseases. For example, GCSAM has been shown to be elevated in the brains of individuals with Alzheimer's disease, a neurodegenerative disorder. Additionally, GCSAM has been shown to be decreased in the blood of individuals with multiple sclerosis, an autoimmune disorder.

GCSAM is also expressed in a variety of tissues and cells throughout the body, which makes it an attractive candidate for use as a biomarker for disease. For example, GCSAM has been shown to be elevated in the livers of individuals with cancer, which suggests that it may be a useful indicator of the disease.

In conclusion, GCSAM is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases. Its interactions with transcription factors and its expression in a variety of tissues make it an attractive candidate for further study. Further research is needed to fully understand the role of GCSAM in the development and progression of these diseases.

Protein Name: Germinal Center Associated Signaling And Motility

Functions: Involved in the negative regulation of lymphocyte motility. It mediates the migration-inhibitory effects of IL6. Serves as a positive regulator of the RhoA signaling pathway. Enhancement of RhoA activation results in inhibition of lymphocyte and lymphoma cell motility by activation of its downstream effector ROCK. Is a regulator of B-cell receptor signaling, that acts through SYK kinase activation

The "GCSAM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GCSAM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets